A NEW class of drug that reduces cancer recurrence and spread may soon be available, with South Australian biopharmaceutical company Bionomics having passed review by the US Food and Drug Administration (FDA) with their product BNC101. The drug targets hard-to-treat colorectal and pancreatic cancers, but may also prove suitable to treat breast, lung and other […]